Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Clin Microbiol Infect Dis ; 28(8): 971-6, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19360444

RESUMEN

The purpose of the study was to compare the clinical characteristics and outcomes of bacteraemic pneumococcal pneumonia (BPP) in chronic obstructive pulmonary disease (COPD) and non-COPD patients. A case-control study was conducted. Cases were any adult with BPP and forced expiratory volume in 1 second (FEV(1)) <80% and FEV(1)/forced expiratory vital capacity (FVC) <70%. Controls were patients with BPP without clinical diagnosis of COPD matched 1:2 by age, gender and date of isolation. Variables included co-morbidities, serotypes, pneumonia severity index (PSI), treatment and mortality. There were 45 cases and 90 controls. No significant differences were found in Charlson scores, antibiotic treatment, serotype distribution and severity. Malignancy, shock and mechanical ventilation were less frequent in COPD patients. One patient died vs 14 controls (p = 0.02). In univariate analysis, shock, multilobar involvement, Charlson score, heart failure and absence of COPD were associated with mortality. After adjustment for the presence of shock there were no differences in mortality. BPP presents less frequently with shock and has a lower mortality rate in COPD patients than in non-COPD patients.


Asunto(s)
Bacteriemia/epidemiología , Bacteriemia/microbiología , Neumonía Neumocócica/complicaciones , Neumonía Neumocócica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Adulto , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/fisiopatología , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neumonía Neumocócica/tratamiento farmacológico , Neumonía Neumocócica/fisiopatología , Factores de Riesgo , Serotipificación , Índice de Severidad de la Enfermedad , Streptococcus pneumoniae/clasificación , Streptococcus pneumoniae/aislamiento & purificación , Análisis de Supervivencia , Resultado del Tratamiento
3.
Enferm Infecc Microbiol Clin ; 17 Suppl 2: 81-5, 1999.
Artículo en Español | MEDLINE | ID: mdl-10605192

RESUMEN

BACKGROUND: Information on patterns of resistance to and cross-resistance between antiretroviral agents is increasingly available and may be important for decisions on how to combine drugs to achieve an optimum antiviral effect in future therapeutic strategies. The increasing number of heavily pre-treated patients have changed the approach to assist therapeutic decision-making in patients failing therapy. Recent studies give us a more comprehensive analysis of the link of such mutations with a rebound in viral load and appearance of drug resistance. However, not all sites of mutations are known and the effects of interactions between them at different codons has not yet been well understood. Moreover, the interpretation is made from generalisations based on drug testing in vitro and there are scarce clinical data available. OBJECTIVE: This work tries to summarize the most important studies to date, in order to know the significance of drug resistance as well as their potential use in everyday clinical practice.


Asunto(s)
Fármacos Anti-VIH/farmacología , Ensayos Clínicos como Asunto , Farmacorresistencia Microbiana , Medicina Basada en la Evidencia , Infecciones por VIH/tratamiento farmacológico , Servicios de Información , Adulto , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/uso terapéutico , Método Doble Ciego , Farmacorresistencia Microbiana/genética , Resistencia a Múltiples Medicamentos/genética , Quimioterapia Combinada , Genotipo , VIH/genética , Inhibidores de la Proteasa del VIH/administración & dosificación , Inhibidores de la Proteasa del VIH/farmacología , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Mutación , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/farmacología , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Insuficiencia del Tratamiento , Carga Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA